Ocuphire Pharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ocuphire Pharma sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Ocuphire Pharma: 14 sponsored US clinical trials, 1 recruiting.
Ocuphire Pharma sponsors 14 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 13 completed. 8 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dilation, with 1 trials.
Top-decile sponsor footprint
Ocuphire Pharma ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
14 total, page 1 of 1
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
NCT07140783
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
NCT06542497
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
NCT06349759
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
NCT05646719
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
NCT05223478
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
NCT05134974
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
NCT04692688
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
NCT04675151
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
NCT04638660
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
NCT04620213
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
NCT04024891
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
NCT03960866
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
NCT01703559
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
NCT04004507
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
| Phase 3 | 8 |
Therapeutic Areas
What is open in the Ocuphire Pharma pipeline
1 recruiting of 14 indexed (7% open); 13 completed (93%).
Phase mix: 8 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Dilation (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ocuphire Pharma: open-pipeline peers nationwide
Peers matched on 14 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Ocuphire Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Ocuphire Pharma page
14 registered trials is a research-attention snapshot, not an endorsement of Ocuphire Pharma or any single study.
- 1 of Ocuphire Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dilation is the condition Ocuphire Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dilation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ocuphire Pharma pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.